<! DOCTYPE = html>
<html>
<title>CS657 - Prescription</title>
<style>
div.container {
		width: 100%;
		border: 1px solid gray;
}

header{
		padding: 0.5em;
		#color: black;
		background-color: orange;
		clear: left;
		text-align: center;
}
.footer{
		padding : 1em;
		background-color: orange;
		text-align: center;
		<!--- position: fixed;>
		bottom : 0;
		width : 100%;
}

nav {
		float: left;
		max-width: 160px;
		margin: 0;
		padding: 1em;
}

nav ul {
		list-style-type: none;
		padding: 0;
}
	 
nav ul a {
		text-decoration: none;
}

article {
		margin-left: 170px;
		border-left: 1px solid gray;
		padding: 1em;
		overflow: hidden;
}
table {
		font-family: arial, sans-serif;
		border-collapse: collapse;
		width: 80%;
}

td, th {
		border: 4px solid #000000;
		text-align: middle;
		padding: 8px;
}

tr:nth-child(even) {
		background-color: #eeeeee;
}	

div.box {
		background-color: white;
		width: 300px;
		border: 2px solid green;
		padding: 10px;
		margin: 25px;
}
</style>
<body>
<div class="container">
	<header><h1>
		IIT Kanpur Medical Labs</h1>
	</header>
	<hr>	<h2> Precription for the query: </h2>
	<div class="box">
	weight loss, thinness, overweight, low body mass index, weight gain
	</div>
	<hr>	<h2>
		Identified Disease: </h2>
	<div class="box">
	Hypertension
	</div>
	<hr>	<h2>More Symptoms: </h2>
	<div class="box">
	Emaciation, Cyanosis, Heart Murmurs, Ataxia, Akathisia
	</div>
		<hr><h2>
Medication:</h2>
<table>
	<tr>
		<th>Serial No</th>
		<th>Drug Name</th>
		<th>Group</th>
		<th>Indication</th>
	</tr>	<tr>
		<td>1.</td>
		<td>Phenoxybenzamine</td>
		<td>Approved</td>
		<td>For the treatment of phaeochromocytoma (malignant), benign prostatic hypertrophy and malignant essential hypertension.</td>
	</tr>	<tr>
		<td>2.</td>
		<td>Riociguat</td>
		<td>Approved</td>
		<td>Riociguat is indicated for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), (WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class.Riociguat is indicated for the treatment of adults with pulmonary arterial hypertension (PAH), (WHO Group 1), to improve exercise capacity, WHO functional class and to delay clinical worsening. Efficacy was shown in patients on Riociguat monotherapy or in combination with endothelin receptor antagonists or prostanoids. Studies establishing effectiveness included predominately patients with WHO functional class II–III and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (25%).</td>
	</tr>	<tr>
		<td>3.</td>
		<td>Bethanidine</td>
		<td>Approved</td>
		<td>For the treatment of hypertension.</td>
	</tr>	<tr>
		<td>4.</td>
		<td>Benzthiazide</td>
		<td>Approved</td>
		<td>For the treatment of high blood pressure and management of edema.</td>
	</tr>	<tr>
		<td>5.</td>
		<td>Quinethazone</td>
		<td>Approved</td>
		<td>Used to treat hypertension.</td>
	</tr>	<tr>
		<td>6.</td>
		<td>Cryptenamine</td>
		<td>Approved</td>
		<td>For the treatment of hypertension.</td>
	</tr>	<tr>
		<td>7.</td>
		<td>Ambrisentan</td>
		<td>Approved, Investigational</td>
		<td>Ambrisentan is indicated for treatment of idiopathic (‘primary’) pulmonary arterial hypertension (IPAH) and pulmonary arterial hypertension (PAH) associated with connective tissue disease in patients with WHO functional class II or III symptoms. In the United States of America, ambrisentan is also indicated in combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability.</td>
	</tr>	<tr>
		<td>8.</td>
		<td>Hydroflumethiazide</td>
		<td>Approved, Investigational</td>
		<td>Used as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Also used in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension.</td>
	</tr>	<tr>
		<td>9.</td>
		<td>Iloprost</td>
		<td>Approved, Investigational</td>
		<td>Used for the treatment of pulmonary arterial hypertension.</td>
	</tr>	<tr>
		<td>10.</td>
		<td>Gadolinium</td>
		<td>Approved, Investigational</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>11.</td>
		<td>Trimethaphan</td>
		<td>Approved, Investigational</td>
		<td>For the controlled reduction of blood pressure during surgery and in the treatment of hypertensive emergencies.</td>
	</tr>	<tr>
		<td>12.</td>
		<td>Mecamylamine</td>
		<td>Approved, Investigational</td>
		<td>For the treatment of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension</td>
	</tr>	<tr>
		<td>13.</td>
		<td>Sitaxentan</td>
		<td>Approved, Investigational, Withdrawn</td>
		<td>Investigated for use/treatment in pulmonary hypertension, connective tissue diseases, hypertension, and congestive heart failure.</td>
	</tr>	<tr>
		<td>14.</td>
		<td>Trichlormethiazide</td>
		<td>Approved, Vet approved</td>
		<td>Used in the treatment of oedema (including that associated with heart failure) and hypertension.</td>
	</tr>	<tr>
		<td>15.</td>
		<td>PF-03187207</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in glaucoma and ocular hypertension.</td>
	</tr>	<tr>
		<td>16.</td>
		<td>Actelion-1</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in cardiovascular disorders, hypertension, and pulmonary hypertension.</td>
	</tr>	<tr>
		<td>17.</td>
		<td>trans NV-04</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in cardiovascular disorders and hypertension.</td>
	</tr>	<tr>
		<td>18.</td>
		<td>PF-00489791</td>
		<td>Investigational</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>19.</td>
		<td>DNB-001</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in ocular hypertension.</td>
	</tr>	<tr>
		<td>20.</td>
		<td>Terbogrel</td>
		<td>Investigational</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>21.</td>
		<td>TBC-3711</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in congestive heart failure, hypertension, and pulmonary hypertension.</td>
	</tr>	<tr>
		<td>22.</td>
		<td>Bamosiran</td>
		<td>Investigational</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>23.</td>
		<td>SPP1148</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in hypertension.</td>
	</tr>	<tr>
		<td>24.</td>
		<td>Forasartan</td>
		<td>Experimental</td>
		<td>For the treatment of hypertension.</td>
	</tr>	<tr>
		<td>25.</td>
		<td>Chlorphentermine</td>
		<td>Illicit, Withdrawn</td>
		<td>Used as an appetite suppressant.</td>
	</tr></table>
<div class="footer"> Copyright &copy : IIT Kanpur
</div>	
</div>
</body>
</html>